Press Releases

Genosity, Inc., an innovative biotechnology company that provides comprehensive software and technical solutions to enable precision medicine announced today that it has entered into a strategic collaboration with Personal Genome Diagnostics Inc. (PGDx), one of the leading companies in cancer genomics, that recently received market clearance from the U.S. Food and Drug Administration (FDA) for PGDx elio™ tissue complete, a comprehensive diagnostic kit for genomic profiling of cancer.

The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis.www.avancecro.com/eclinical-solutions Avance Clinical made the announcement at BioPharm America (September 21-24, 2020) Avance Clinical's biotech clients now have the option to depl

Europital – a globally-focused full service CRO serving small and mid-tier innovators – announces a significant expansion as it launches new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing services of Medical Affairs and Medical Writing. The expanded clinical research offering will see Europital support clients as a full service CRO in over 40 countries from IND throu

OnKure, Inc., a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to support the clinical proof of concept study for MEKTOVI® (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma. Activating NRAS mutations occur in approximately 20% of melanomas,

Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutics, which could be increased to $545.6 million. By leveraging Samsung Biologics' robust expertise and capabilities in the manufacturing of high-quality biopharmaceuticals,

Immune Regulation Limited, a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside Ventures (“Morningside”), alongside existing shareholders including London based 24Haymarket. The investment round is structured in two tranches and includes an option for Morningside to invest further capital at a step up to the initial two tranches. In addition, Immune Regulation has raised £6 million / $

Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, announced that the first patient has been enrolled in the “CURE” study. Top-line Data for the “CURE” Study Anticipated in Fourth Quarter 2021 In times of COVID-19, conducting a clinical trial that does not contribute to fighting the pandemic is doubly difficult. Neverth

A novel, oral osteoarthritis (OA) medicine being developed by AKL Research and Development (AKLRD) has recruited its first patient into its Phase II human clinical trial being conducted by its partner Nordic Bioscience Clinical Development (NBCD), following the successful completion of Phase I. David Miles, CEO of UK-based AKLRD, says: "Osteoarthritis is a debilitating condition which has a devastating impact on the daily lives of millions of people. Moving to a Phase II trial

Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven (generic name: eribulin mesylate, "eribulin") were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. E7389-LF is a new formulation using liposomes made of a lipid bilay

Dyadic International, Inc., a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic drug(s). "We are very